777 related articles for article (PubMed ID: 11017796)
1. Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication.
Van Scoy S; Watakabe I; Krainer AR; Hearing J
Virology; 2000 Sep; 275(1):145-57. PubMed ID: 11017796
[TBL] [Abstract][Full Text] [Related]
2. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus.
Wang Y; Finan JE; Middeldorp JM; Hayward SD
Virology; 1997 Sep; 236(1):18-29. PubMed ID: 9299613
[TBL] [Abstract][Full Text] [Related]
3. An imperfect correlation between DNA replication activity of Epstein-Barr virus nuclear antigen 1 (EBNA1) and binding to the nuclear import receptor, Rch1/importin alpha.
Kim AL; Maher M; Hayman JB; Ozer J; Zerby D; Yates JL; Lieberman PM
Virology; 1997 Dec; 239(2):340-51. PubMed ID: 9434725
[TBL] [Abstract][Full Text] [Related]
4. Epstein-barr virus nuclear antigen-1 binds to nuclear transporter karyopherin alpha1/NPI-1 in addition to karyopherin alpha2/Rch1.
Ito S; Ikeda M; Kato N; Matsumoto A; Ishikawa Y; Kumakubo S; Yanagi K
Virology; 2000 Jan; 266(1):110-9. PubMed ID: 10612665
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes.
McClain K; Estrov Z; Raju U; Kelley PK; Aggarwal BB
Methods; 1997 Jan; 11(1):83-7. PubMed ID: 8990093
[TBL] [Abstract][Full Text] [Related]
6. Latent and lytic Epstein-Barr virus replication strategies.
Tsurumi T; Fujita M; Kudoh A
Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
8. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle.
Evans TJ; Jacquemin MG; Farrell PJ
Virology; 1995 Feb; 206(2):866-77. PubMed ID: 7856099
[TBL] [Abstract][Full Text] [Related]
9. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
[TBL] [Abstract][Full Text] [Related]
10. Protein and sequence requirements for the recruitment of the human origin recognition complex to the latent cycle origin of DNA replication of Epstein-Barr virus oriP.
Julien MD; Polonskaya Z; Hearing J
Virology; 2004 Sep; 326(2):317-28. PubMed ID: 15302216
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
[TBL] [Abstract][Full Text] [Related]
12. Initiation of DNA replication within oriP is dispensable for stable replication of the latent Epstein-Barr virus chromosome after infection of established cell lines.
Norio P; Schildkraut CL; Yates JL
J Virol; 2000 Sep; 74(18):8563-74. PubMed ID: 10954558
[TBL] [Abstract][Full Text] [Related]
13. Pleiotrophic functions of Epstein-Barr virus nuclear antigen-1 (EBNA-1) and oriP differentially contribute to the efficiency of transfection/expression of exogenous gene in mammalian cells.
Kishida T; Asada H; Kubo K; Sato YT; Shin-Ya M; Imanishi J; Yoshikawa K; Mazda O
J Biotechnol; 2008 Jan; 133(2):201-7. PubMed ID: 17935815
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus nuclear antigen-1-dependent and -independent oriP-binding cellular proteins.
Kusano S; Tamada K; Senpuku H; Harada S; Ito S; Yanagi K
Intervirology; 2001; 44(5):283-90. PubMed ID: 11684889
[TBL] [Abstract][Full Text] [Related]
15. Requirement of replication licensing for the dyad symmetry element-dependent replication of the Epstein-Barr virus oriP minichromosome.
Shirakata M; Imadome KI; Hirai K
Virology; 1999 Oct; 263(1):42-54. PubMed ID: 10544081
[TBL] [Abstract][Full Text] [Related]
16. De novo DNA methylation at nonrandom founder sites 5' from an unmethylated minimal origin of DNA replication in latent Epstein-Barr virus genomes.
Salamon D; Takacs M; Myöhänen S; Marcsek Z; Berencsi G; Minarovits J
Biol Chem; 2000 Feb; 381(2):95-105. PubMed ID: 10746740
[TBL] [Abstract][Full Text] [Related]
17. Sequence requirements of the Epstein-Barr virus latent origin of DNA replication.
Harrison S; Fisenne K; Hearing J
J Virol; 1994 Mar; 68(3):1913-25. PubMed ID: 8107251
[TBL] [Abstract][Full Text] [Related]
18. Modulation of expression of insulin and IGF-I receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines.
Kriauciunas KM; Goldstein BJ; Lipes MA; Kahn CR
J Cell Physiol; 1993 Mar; 154(3):486-95. PubMed ID: 8382208
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis for Cooperative Binding of EBNA1 to the Epstein-Barr Virus Dyad Symmetry Minimal Origin of Replication.
Malecka KA; Dheekollu J; Deakyne JS; Wiedmer A; Ramirez UD; Lieberman PM; Messick TE
J Virol; 2019 Oct; 93(20):. PubMed ID: 31142669
[TBL] [Abstract][Full Text] [Related]
20. Interactions of Epstein-Barr virus origins of replication with nuclear matrix in the latent and in the lytic phases of viral infection.
Mattia E; Ceridono M; Chichiarelli S; D'Erme M
Virology; 1999 Sep; 262(1):9-17. PubMed ID: 10489336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
